See more : Athena Gold Corporation (AHNR) Income Statement Analysis – Financial Results
Complete financial analysis of RespireRx Pharmaceuticals Inc. (RSPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RespireRx Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Public Joint Stock Company “TNS energo Kuban” (KBSB.ME) Income Statement Analysis – Financial Results
- Media Central Corporation Inc. (FLYY.CN) Income Statement Analysis – Financial Results
- Nongfu Spring Co., Ltd. (NNFSF) Income Statement Analysis – Financial Results
- Globaltech Holdings, Inc. (GLBH) Income Statement Analysis – Financial Results
- HORIZON FIXTURE GROUP CO LTD (6957.TW) Income Statement Analysis – Financial Results
RespireRx Pharmaceuticals Inc. (RSPI)
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.92K | 61.67K | 0.00 | 48.31K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.51M | 3.15M | 130.00K | 0.00 | 0.00 | 100.00K | 100.00K | 2.60M | 1.00M | 100.00K | 100.00K | 100.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.17K | 6.95K | 1.71K | 591.77 | 206.91 | 826.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 4.10M | 2.80M | 1.80M | 2.10M | 1.80M | 2.40M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.17K | -6.95K | 85.21K | 61.08K | -206.91 | 47.48K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.68M | 3.15M | 130.00K | 0.00 | 0.00 | -4.00M | -2.70M | 800.00K | -1.10M | -1.70M | -2.30M | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 98.04% | 99.04% | 0.00% | 98.29% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 103.14% | 100.00% | 100.00% | 0.00% | 0.00% | -4,000.00% | -2,700.00% | 30.77% | -110.00% | -1,700.00% | -2,300.00% | 100.00% | 0.00% |
| Research & Development | 429.53K | 702.04K | 638.28K | 599.33K | 688.29K | 1.73M | 3.18M | 1.71M | 591.77K | 206.91K | 826.70K | 2.19M | 3.74M | 4.60M | 10.78M | 9.33M | 13.26M | 11.18M | 6.12B | 3.80M | 5.04M | 4.41M | 3.90M | 3.38M | 4.01M | 3.38M | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 110.00K |
| General & Administrative | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 3.38B | 3.39B | 2.29B | 2.62B | 2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -397.00 | -82.00 | -3.37B | -3.39B | 0.00 | -2.62B | -2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 4.62M | 3.56M | 2.29B | 2.62M | 2.44M | 2.43M | 1.81M | 1.40M | 1.58M | 1.71M | 1.64M | 2.90M | 2.00M | 1.40M | 1.30M | 900.00K | 0.00 | 1.30M | 220.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.62M | 1.11B | 0.00 | 0.00 | 0.00 | 172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 0.00 | 10.00K |
| Operating Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.88M | 4.78M | 5.59M | 5.09M | 4.32M | 3.10M | 2.20M | 1.60M | 1.40M | 1.00M | 100.00K | 1.30M | 340.00K |
| Cost & Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.71M | 4.78M | 5.59M | 5.09M | 4.32M | 7.20M | 5.00M | 3.40M | 3.50M | 2.80M | 2.50M | 1.30M | 340.00K |
| Interest Income | 603.82 | 724.77 | 545.68 | 404.66 | 0.00 | 0.00 | 8.00 | 9.00 | 0.00 | 0.00 | 92.00 | 1.86K | -8.50K | 16.58K | 443.06K | 678.05K | 645.82K | 637.37K | 0.00 | 0.00 | 72.14K | 254.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 603.82K | 724.77K | 545.68K | 404.66K | 136.24K | 102.23K | 586.35K | 902.70K | 117.31K | 56.34K | 196.98K | 4.02K | 1.63M | -8.44M | -14.60M | -12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.93M | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K |
| Depreciation & Amortization | 80.45K | 2.56M | 3.32M | 1.74M | 5.17K | 5.17K | 6.95K | 7.12K | 1.66K | -7.22K | 115.86K | 106.97K | 112.48K | 186.94K | 164.89K | 126.85K | 110.79K | 125.98K | 0.00 | 155.85K | 153.18K | 149.48K | 172.76K | 197.66K | 201.66K | 198.06K | 230.22K | -200.00K | -200.00K | -200.00K | -100.00K | 100.00K | 100.00K | 20.00K | 50.00K |
| EBITDA | -1.50M | -963.75K | -2.43M | -378.53K | -2.46M | -4.24M | -8.46M | -5.05M | -2.59M | -1.14M | -7.26M | -2.15M | 2.29M | -8.25M | -14.43M | -12.84M | -15.94M | -11.50M | -2.54B | -1.03M | -901.60K | -2.25M | -30.01K | -1.43M | -5.26M | -4.89M | -4.09M | -7.10M | -5.00M | -600.00K | -2.50M | -2.60M | -2.30M | -1.20M | -290.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,020.17% | -7,057.06% | 0.00% | -5,400.72% | -69.18% | 21.99% | -72,951.27% | 0.00% | -54,081.46% | -1,408.95% | -463.68% | -36.43% | -19.75% | -14.02% | -50.61% | -0.54% | -45.45% | -4,046.29% | 0.00% | 0.00% | -7,100.00% | -5,000.00% | -23.08% | -250.00% | -2,800.00% | -2,500.00% | -1,300.00% | 0.00% |
| Operating Income | -1.58M | -2.56M | -3.32M | -1.74M | -2.18M | -4.25M | -8.47M | -5.24M | -4.35M | -1.14M | -7.33M | -2.26M | 2.18M | -8.33M | -15.04M | -13.65M | -16.70M | -12.16M | -2.54B | -1.19M | -1.05M | -2.40M | -202.77K | -1.63M | -5.46M | -5.09M | -4.32M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.22M | -340.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,028.37% | -7,059.75% | 0.00% | -15,177.09% | -72.62% | 20.83% | -75,770.52% | 0.00% | -54,588.86% | -1,418.36% | -471.78% | -36.43% | -22.73% | -16.40% | -53.98% | -3.68% | -51.72% | -4,201.41% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,220.00% | 0.00% |
| Total Other Income/Expenses | -523.37K | -585.71K | -986.08K | -378.53K | -415.27K | -44.07K | -757.87K | -722.28K | 1.65M | -63.56K | -240.34K | 6.95K | -553.30K | -106.60K | 443.06K | 678.05K | 645.82K | 554.38K | 0.00 | 14.51K | 72.14K | 2.40M | 5.37K | 8.48K | 203.88K | 155.62K | 163.06K | 200.00K | 300.00K | 0.00 | 100.00K | 200.00K | 200.00K | 100.00K | 20.00K |
| Income Before Tax | -2.10M | -3.14M | -4.30M | -2.12M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| Income Tax Expense | -80.45K | 724.77K | 545.68K | 404.66K | 279.02K | 44.07K | 757.87K | 722.28K | -1.65M | 7.22K | 4.85M | 2.25M | -1.63M | 8.44M | 14.60M | 12.97M | 16.05M | 11.61M | 0.00 | 1.17M | 982.64K | 2.67M | 197.40K | 1.62M | 5.26M | 4.93M | 4.16M | 6.80M | 4.70M | 800.00K | 2.40M | 2.60M | 2.20M | 1.20M | -50.00K |
| Net Income | -3.97M | -3.87M | -4.85M | -2.52M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -270.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| EPS | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -191.10 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| EPS Diluted | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -177.31 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| Weighted Avg Shares Out | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.14K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
| Weighted Avg Shares Out (Dil) | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.54K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling,...
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling,...
RespireRx's key asset moves to next stage of NIH initiative
RespireRx Pharmaceuticals (OTC:RSPI) Inc, a pioneer in the field of neuronal signaling treatments, said its lead compound, KRM-II-81, has progressed to the next evaluation phase of the National Institutes for Health's HEAL Initiative's Preclinical Screening Platform for Pain (PSPP) program. In doing so...
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal...
RespireRx Pharmaceuticals strengthens board, adding new director
RespireRx Pharmaceuticals (OTC:RSPI) has strengthened its board, with the appointment of Dr Dariusz Nasiek as a director. The drug discovery firm focussed on psychiatric and neurological disorders, in a statement, said that Nasiek brings valuable experience to the board with his background in...
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling,...
RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81
RespireRx Pharmaceuticals (OTC:RSPI) said a case study demonstrating positive results from the treatment of an epilepsy patient involving its therapeutic KRM-II-81 has been published in a peer-reviewed journal. The company said that the 19-year-old patient in the case study had...
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal...
RespireRX Pharmaceuticals announces Ponto Ventures' MD Will Clodfelter will help drive business development
RespireRx Pharmaceuticals (OTC:RSPI) has announced an agreement with Ponto Ventures LLC under which Will Clodfelter will serve as its senior vice president of business development on a part-time basis. Clodfelter is the founder and managing director of Ponto Ventures, a biotech...
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a biopharmaceutical company focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption...
Source: https://incomestatements.info
Category: Stock Reports